Fifteen Years of Immunological Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the CVT (Costa Rican HPV-16 18 Vaccine Trial) or the CVT EXTEND Study

Trial Profile

Fifteen Years of Immunological Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the CVT (Costa Rican HPV-16 18 Vaccine Trial) or the CVT EXTEND Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms CVT EXTEND
  • Most Recent Events

    • 08 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 17 Nov 2017.
    • 26 Oct 2017 Planned initiation date changed from 31 Oct 2017 to 1 Nov 2017.
    • 24 Oct 2017 Planned initiation date changed from 20 Oct 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top